European Respiratory Journal最新文献

筛选
英文 中文
Unravelling the physiology of exercise pulmonary hypertension in patients with heart failure with preserved ejection fraction. 对保留射血分数的心力衰竭患者运动性肺动脉高压的生理学研究。
IF 24.3 1区 医学
European Respiratory Journal Pub Date : 2025-05-06 DOI: 10.1183/13993003.00384-2025
Ajay Kumar Jha
{"title":"Unravelling the physiology of exercise pulmonary hypertension in patients with heart failure with preserved ejection fraction.","authors":"Ajay Kumar Jha","doi":"10.1183/13993003.00384-2025","DOIUrl":"https://doi.org/10.1183/13993003.00384-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"12 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143920991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tuberculosis Preventive Treatment care pathways in people living with HIV: a systematic review and meta-analysis. 艾滋病毒感染者的结核病预防治疗护理途径:系统回顾和荟萃分析。
IF 24.3 1区 医学
European Respiratory Journal Pub Date : 2025-05-01 DOI: 10.1183/13993003.02174-2023
Svetlana Degtyareva,Yohhei Hamada,Rebecca F Baggaley,Nasser Hassan,Santino Capocci,Reinout van Crevel,Dorine van Geuns,Robert Miller,Manish Pareek,Anton Pozniak,Molebogeng Xheedha Rangaka,Simon Tiberi,Gerard de Vries,Marc Lipman,James Brown
{"title":"Tuberculosis Preventive Treatment care pathways in people living with HIV: a systematic review and meta-analysis.","authors":"Svetlana Degtyareva,Yohhei Hamada,Rebecca F Baggaley,Nasser Hassan,Santino Capocci,Reinout van Crevel,Dorine van Geuns,Robert Miller,Manish Pareek,Anton Pozniak,Molebogeng Xheedha Rangaka,Simon Tiberi,Gerard de Vries,Marc Lipman,James Brown","doi":"10.1183/13993003.02174-2023","DOIUrl":"https://doi.org/10.1183/13993003.02174-2023","url":null,"abstract":"BACKGROUNDTuberculosis Preventive Treatment (TPT) can reduce TB incidence and mortality in people living with HIV. However, low levels of screening and uptake, poor adherence, and loss to follow-up considerably reduce its effectiveness. We aimed, therefore, to assess the losses within all steps of the screening and treatment cascade.METHODSTo enhance data generalizibility we included articles which reported the proportion of people living with HIV completing any step of the TPT cascade in low- and high-TB burden countries published before March 2024. Random effects meta-analysis produced pooled estimates of the proportion proceeding to the next step along the cascade. Results were explored through subgroup analyses and meta-regression. PROSPERO registration: CRD42020162396.FINDINGSData from 368 cohorts containing 2.7 million participants were included. High levels of heterogeneity in outcomes were seen. Most participants were from Africa (80.6%). Isoniazid monotherapy was used for TPT in 92.6% of cohorts, usually for six months. Substantial loss to follow-up was found throughout the treatment cascade with more than one in six patients lost at the following steps: initial screening, immunological testing, treatment start and completion. Treatment regimens lasting four months or less were more likely to be completed than longer ones - 88.4% compared to 61.6%.INTERPRETATIONOur analysis highlights substantial loss to follow-up at multiple steps during the care cascade. This may significantly lower the reported effectiveness of TPT in real-world settings. Research and policy should focus on simplified care pathways and novel, shorter treatment regimens that optimise retention in care.","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"9 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ERJ Podcast April 2025: Continuous positive airway pressure and mandibular advancement splints. ERJ播客2025年4月:持续气道正压和下颌前移夹板。
IF 24.3 1区 医学
European Respiratory Journal Pub Date : 2025-04-30 DOI: 10.1183/13993003.e6504-2025
{"title":"ERJ Podcast April 2025: Continuous positive airway pressure and mandibular advancement splints.","authors":"","doi":"10.1183/13993003.e6504-2025","DOIUrl":"https://doi.org/10.1183/13993003.e6504-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"53 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143897462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial. 吡非尼酮治疗covid - 19后肺纤维化(纤维- covid):一项2期随机临床试验
IF 16.6 1区 医学
European Respiratory Journal Pub Date : 2025-04-24 Print Date: 2025-04-01 DOI: 10.1183/13993003.02249-2024
Guadalupe Bermudo-Peloche, Belén Del Rio, Vanesa Vicens-Zygmunt, Jaume Bordas-Martinez, Marta Hernández, Claudia Valenzuela, Rosalía Laporta, Juan Rigual Bobillo, Karina Portillo, Paloma Millán-Billi, Eva Balcells, Diana Badenes-Bonet, Santi Bolivar, José-Antonio Rodríguez-Portal, Cecilia López Ramirez, Laura Tomás, Koral Fernández de Roitegi, Jacobo Sellarés, Diego Castillo, Jessica González, Silvia Barril, Yasmina Gutiérrez-Rodríguez, Paloma Caballero, Javier Alarcon, Judith Peñafiel, Jose Sanz-Santos, Rosana Blavia, Cristina Caupena, Pilar Segovia, Salud Santos-Pérez, Anna Ferrer-Artola, Maria B Badia, Pilar Hereu, Mireya Fuentes, Ana Montes-Worboys, Tomás Franquet, Patricio Luburich, María Molina-Molina
{"title":"Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial.","authors":"Guadalupe Bermudo-Peloche, Belén Del Rio, Vanesa Vicens-Zygmunt, Jaume Bordas-Martinez, Marta Hernández, Claudia Valenzuela, Rosalía Laporta, Juan Rigual Bobillo, Karina Portillo, Paloma Millán-Billi, Eva Balcells, Diana Badenes-Bonet, Santi Bolivar, José-Antonio Rodríguez-Portal, Cecilia López Ramirez, Laura Tomás, Koral Fernández de Roitegi, Jacobo Sellarés, Diego Castillo, Jessica González, Silvia Barril, Yasmina Gutiérrez-Rodríguez, Paloma Caballero, Javier Alarcon, Judith Peñafiel, Jose Sanz-Santos, Rosana Blavia, Cristina Caupena, Pilar Segovia, Salud Santos-Pérez, Anna Ferrer-Artola, Maria B Badia, Pilar Hereu, Mireya Fuentes, Ana Montes-Worboys, Tomás Franquet, Patricio Luburich, María Molina-Molina","doi":"10.1183/13993003.02249-2024","DOIUrl":"10.1183/13993003.02249-2024","url":null,"abstract":"<p><strong>Background: </strong>Patients with severe COVID-19 may develop lung fibrosis. Pirfenidone is an anti-fibrotic drug approved for idiopathic pulmonary fibrosis. The efficacy and safety of pirfenidone in patients with fibrotic interstitial lung changes after recovery from severe COVID-19 pneumonia were evaluated.</p><p><strong>Methods: </strong>This was a phase 2, double-blind, placebo-controlled, Spanish multicentre clinical trial. Patients were randomised to receive pirfenidone or placebo (2:1) for 24 weeks. The primary end-point was the proportion of patients that improved, considered when percentage change in forced vital capacity (FVC) was ≥10% and/or any reduction in the fibrotic score on chest high-resolution computed tomography (HRCT). Secondary end-points included health-related quality of life (HRQoL), exercise capacity and drug safety profile.</p><p><strong>Results: </strong>From 119 eligible patients, 113 were randomised and 103 were analysed (pirfenidone n=69 and placebo n=34). Most patients were male (73.5%) and were receiving low-dose prednisone; mean age was 63.7 years and mean body mass index was 29 kg·m<sup>-2</sup>. The percentage of patients that improved was similar in the pirfenidone and placebo groups (79.7% <i>versus</i> 82.3%, respectively). The mean predicted FVC increased by 12.74±20.6% with pirfenidone and 4.35±22.3% with placebo (p=0.071), and the HRCT (%) fibrotic score decreased by 5.44±3.69% with pirfenidone and 2.57±2.59% with placebo (p=0.52). Clinically meaningful improvement in HRQoL was not statistically different (55.2% in the pirfenidone group and 39.4% in the placebo group). Exercise capacity, adverse events and hospitalisations were similar between groups. No deaths were reported.</p><p><strong>Conclusions: </strong>The overall improvements in lung function and HRCT fibrotic score after 6 months with pirfenidone were not significantly different than with placebo.</p>","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12018760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Advancing patient-centred care in measuring response to biologics in severe asthma." Vanesa Bellou. Eur Respir J 2025; 65: 2402113. “推进以患者为中心的护理,测量严重哮喘患者对生物制剂的反应。”Vanesa Bellou。中华呼吸病学杂志[J];65: 2402113。
IF 24.3 1区 医学
European Respiratory Journal Pub Date : 2025-04-24 DOI: 10.1183/13993003.52113-2024
{"title":"\"Advancing patient-centred care in measuring response to biologics in severe asthma.\" Vanesa Bellou. Eur Respir J 2025; 65: 2402113.","authors":"","doi":"10.1183/13993003.52113-2024","DOIUrl":"https://doi.org/10.1183/13993003.52113-2024","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"133 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143876385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond immunosuppression: decoding systemic immune dysregulation in ICU-acquired pneumonia. 超越免疫抑制:解码重症监护病房获得性肺炎的全身免疫失调。
IF 24.3 1区 医学
European Respiratory Journal Pub Date : 2025-04-24 DOI: 10.1183/13993003.00185-2025
Lucile P A Neyton,Michael A Matthay,Charles S Dela Cruz,Alicia N Rizzo
{"title":"Beyond immunosuppression: decoding systemic immune dysregulation in ICU-acquired pneumonia.","authors":"Lucile P A Neyton,Michael A Matthay,Charles S Dela Cruz,Alicia N Rizzo","doi":"10.1183/13993003.00185-2025","DOIUrl":"https://doi.org/10.1183/13993003.00185-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"29 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143876383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in detecting small airway disease with medical imaging. 医学影像学检测小气道疾病的研究进展。
IF 16.6 1区 医学
European Respiratory Journal Pub Date : 2025-04-24 Print Date: 2025-04-01 DOI: 10.1183/13993003.00212-2025
Kalysta Makimoto, Gaurav Veer Singh, Miranda Kirby
{"title":"Advances in detecting small airway disease with medical imaging.","authors":"Kalysta Makimoto, Gaurav Veer Singh, Miranda Kirby","doi":"10.1183/13993003.00212-2025","DOIUrl":"10.1183/13993003.00212-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects? Lunsekimig双特异性靶向IL-13和TSLP治疗哮喘:双靶点协同效应?
IF 24.3 1区 医学
European Respiratory Journal Pub Date : 2025-04-24 DOI: 10.1183/13993003.00153-2025
Mohamed-Ilias Kourid,Simon Couillard
{"title":"Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?","authors":"Mohamed-Ilias Kourid,Simon Couillard","doi":"10.1183/13993003.00153-2025","DOIUrl":"https://doi.org/10.1183/13993003.00153-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"8 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143876430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fine particulate matter and interstitial lung disease in systemic autoimmune rheumatic diseases. 细颗粒物与系统性自身免疫性风湿病的间质性肺病
IF 16.6 1区 医学
European Respiratory Journal Pub Date : 2025-04-24 Print Date: 2025-04-01 DOI: 10.1183/13993003.02403-2024
Naizhuo Zhao, Ziyad Al-Aly, Aaron van Donkelaar, Randall V Martin, Deborah Assayag, Christian A Pineau, Sasha Bernatsky
{"title":"Fine particulate matter and interstitial lung disease in systemic autoimmune rheumatic diseases.","authors":"Naizhuo Zhao, Ziyad Al-Aly, Aaron van Donkelaar, Randall V Martin, Deborah Assayag, Christian A Pineau, Sasha Bernatsky","doi":"10.1183/13993003.02403-2024","DOIUrl":"10.1183/13993003.02403-2024","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"BR22, a 26 kDa thyroid transcription factor-1 associated protein (TAP26), is expressed in human lung cells." M-C.W. Yang, B. Wang, J.C. Weissler, L.R. Margraf and Y-S. Yang. Eur Respir J 2003; 22: 28-34. “BR22是一种26 kDa的甲状腺转录因子-1相关蛋白(TAP26),在人肺细胞中表达。”M-C.W。杨斌,王宝成,魏斯勒,马格拉夫,杨志强。杨。中华呼吸病学杂志2003;22: 28-34。
IF 24.3 1区 医学
European Respiratory Journal Pub Date : 2025-04-24 DOI: 10.1183/09031936.03.50117702
{"title":"\"BR22, a 26 kDa thyroid transcription factor-1 associated protein (TAP26), is expressed in human lung cells.\" M-C.W. Yang, B. Wang, J.C. Weissler, L.R. Margraf and Y-S. Yang. Eur Respir J 2003; 22: 28-34.","authors":"","doi":"10.1183/09031936.03.50117702","DOIUrl":"https://doi.org/10.1183/09031936.03.50117702","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"58 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143876426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信